OncoMatch/Clinical Trials/NCT06993675
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Is NCT06993675 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Talquetamab and Teclistamab for multiple myeloma.
Treatment: Talquetamab · Teclistamab — Multiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis than those with MRD negative disease. Bispecific T-cell-based immunotherapies have the potential to promote further reduction of malignant plasma cells thus improving rates of MRD negativity and improve patient outcomes. In this study, participants who are MRD positive after front line therapy will receive consolidation with GPRC5D-targeted bispecific talquetamab. We will test MRD negative conversion and if MRD negativity was not achieved, the participant will switch to a different target using the B-cell maturation antigen TCE, teclistamab. Consolidation will be continued for up to 1 year in participants who have achieved MRD negativity. After consolidation therapy on this protocol is complete, participants may continue to be treated with standardof- care (SOC) maintenance therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: quadruplet, anti-CD38 antibody-based induction — newly diagnosed multiple myeloma
have completed at least four cycles of quadruplet, anti-CD38 antibody-based induction
Must have received: high-dose melphalan autologous stem cell transplant — newly diagnosed multiple myeloma
have received HDM ASCT within 60-120 days
Cannot have received: bispecific T-cell engager
Prior exposure to a bispecific T-cell engager
Cannot have received: CAR-T cell therapy
Prior exposure to ... CAR T-cell therapy
Lab requirements
Blood counts
Hemoglobin ≥8 g/dL (no transfusion within 7 days); ANC ≥1.0×10^9/L (no growth factor support within 7 days for G-CSF/GM-CSF, 14 days for pegylated-G-CSF); Platelets ≥75×10^9/L (no transfusion/thrombopoietin receptor agonist within 7 days)
Kidney function
Estimated creatinine clearance ≥30 mL/min (Cockcroft-Gault Equation)
Liver function
AST ≤2.5x ULN; ALT ≤2.5x ULN; serum bilirubin ≤1.5x ULN (except Gilbert syndrome <5x ULN)
Adequate bone marrow function: Hemoglobin 8 g/dl (³5mmol/L; without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted). Absolute neutrophil count ≥1.0×109/L (prior growth factor support is permitted but must be without support for 7 days for G-CSF or GM-CSF and for 14 days for pegylated-G-CSF). Platelets ³75×109/L (without transfusion support or thrombopoietin receptor agonist within 7 days before the laboratory test). Estimated creatinine clearance ≥30 mL/min based on the Cockcroft-Gault Equation. Must have adequate liver function: AST ≤2.5x ULN; ALT ≤2.5x ULN; serum bilirubin ≤1.5x ULN (except Gilbert syndrome <5x ULN).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale University · New Haven, Connecticut
- Wilmot Cancer Center, Clinical Trial Office of the University of Rochester Medical Center · Rochester, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06993675 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bispecific T-cell engager, CAR-T cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages